Sodium Reduction Program Incorporating Genetic Profile and an AI-Based App: A Randomized Clinical Trial
Koryu Sato1,2, Kosuke Inoue2,3, Taihei Yamaguchi4
1Faculty of Policy Management, Keio University, Kanagawa, Japan.
Importance:
Excess salt intake is a major modifiable risk factor for hypertension and cardiovascular disease. Personalized interventions using genetic information and digital tools, such as smartphone applications, may enhance sodium reduction, but evidence remains limited.
Objective:
To evaluate the effectiveness of a sodium reduction program incorporating a genetic profile and an artificial intelligence (AI)-based mobile app among adults with elevated blood pressure and a sodium-sensitive genotype.
Design, Setting, And Participants:
A 3-arm randomized clinical trial, conducted at a Japanese electronics company from September 17 to December 16, 2024, included employees aged 20 to 65 years with elevated blood pressure and the sodium-sensitive AGT M235T genotype.
Interventions:
Participants were randomized on a 1:1:0.2 basis to (1) a treatment group receiving a genetic profile and an AI-based app incorporating sodium-specific information; (2) a control group receiving no intervention; or (3) an app-only group using the app without a genetic profile or information.
Main Outcomes And Measures:
The primary outcome was daily salt intake, estimated from spot urine samples using the INTERSALT (International Study of Electrolyte Excretion and Blood Pressure) formula. Secondary outcomes included self-reported body mass index, behavior change intentions, and systolic and diastolic blood pressure. Analysis was performed on an intention-to-treat basis.
Results:
Of 312 randomized participants, 289 completed follow-up (mean [SD] age, 51.3 [8.3] years; 252 of 279 men [90.3%]). The mean (SD) baseline salt intake was 11.3 (2.0) g/d. At 3 months, no significant difference in salt intake was observed between the treatment and control groups (mean difference, -0.2 g/d; 95% CI, -0.7 to 0.3 g/d) or between the treatment and app-only groups (mean difference, -0.04 g/d; 95% CI, -0.9 to 0.8 g/d). No significant differences were observed between groups in any secondary outcomes.
Conclusions And Relevance:
In this randomized clinical trial conducted among individuals with elevated blood pressure and a sodium-sensitive genotype, a sodium reduction program combining a genetic profile and an AI-based app with sodium-specific information did not significantly reduce salt intake. These findings highlight the challenges of achieving dietary behavior change through genetic personalized plus digital interventions.
Trial Registration:
http://umin.ac.jp/ctr Identifier: UMIN000052685.
Related Concept Videos
Clinical Trials
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview


